Incretin therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors

REFERENCES

• Drucker DJ, Nauck MA. The incretin sys-tem: glucagon-like peptide-1 receptor ago-nists and dipeptidyl peptidase4 inhibitors in type 2 diabetes. Lancet 2006;368: 1696–705.
   PubMed Web of Science ®Google Scholar
• Dunning BE, et al. Alpha-cell function in health and disease: influence of GLP-1. Diabetologia 2005;48:1700–13.
   PubMed Web of Science ®Google Scholar
• Nauck MA, et al. Glucagon-like peptide-1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 1997;273(5 Pt 1):E981–8.
   PubMed Web of Science ®Google Scholar
• Gutzwiller JP, et al. Glucagon-like peptide-1promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 1999;276:R1541–4.
   PubMed Web of Science ®Google Scholar
• Ahrén B. GLP-1 for type 2 diabetes. Exp Cell Res 2011;317:1239–45.
   PubMed Web of Science ®Google Scholar
• Gutniak M, et al. Antidiabetic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med 1992;326:1316–22.
   PubMed Web of Science ®Google Scholar
• Zander M, et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic con-trol, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002;359:824–30.
   PubMed Web of Science ®Google Scholar
• Deacon CF, et al. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2 terminus in type II diabetic patients and in healthy subjects. Diabetes 1995;44:1125–31.
   Web of Science ®Google Scholar
• Ahrén B. GLP-1-based therapy of type 2 dia-betes: GLP-1 mimetics and DPP-W inhibitors. Curr Diabet Rep 2007;7:340–7.
   PubMedGoogle Scholar
• Meier JJ. GLP-1 receptor agonists for individ-ualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012;109:728–42.
   Web of Science ®Google Scholar
• Scott LJ. Exenatide extended-release: a review of its use in type 2 diabetes mellitus. Drugs 2012;72:1679–707.
   PubMed Web of Science ®Google Scholar
• Keta R, Davies MJ. Treatment evaluation of liraglutide in type 2 diabetes. Exp Opin Biol Ther 2012;12:1551–6.
   PubMed Web of Science ®Google Scholar
• Drucker DJ, et al. Exenatide once weekly ver-sus twice daily for the treatment of type 2 diabetes: a randomized, open-label, non-inferiority study. Lancet 2008;372:1240–50.
   PubMed Web of Science ®Google Scholar
• Buse JB, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a ran-domised, open-label study. Lancet 2013;381: 117–24.
   PubMed Web of Science ®Google Scholar
• Fineman MS, et aL GLP-1 based therapies: dif-ferential effects on fasting and postprandial glucose. Diabetes Obes Metab 2012;14:675–88.
   PubMed Web of Science ®Google Scholar
• Ahrén B, et al. Inhibition of dipeptidyl pepti-dase IV improves metabolic control over a 4 week study period in type 2 diabetes. Diabetes Care 2002;25:869–75.
   PubMed Web of Science ®Google Scholar
• Deacon CF. Dipeptidyl peptidase4 inhibitors in the treatment of type 2 diabetes: a com-parative review. Diabetes Obes Metab 2011; 13:7–18.
   PubMed Web of Science ®Google Scholar
• Ahrén B. Use of DPP4 inhibitors in type 2 diabetes: focus on sitagliptin. Diabetes Obes Metab 2010;3:31–41.
   Google Scholar
• Ahrén B. Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin - diabetes control and poten-tial adverse events. Best Pract Res Chn Endocrinol Metab 2009;23:487–98.
   PubMed Web of Science ®Google Scholar
• Deeks ED. Linagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 2012;762:1793–824.
   Web of Science ®Google Scholar
• Deacon CF, et al. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl pepddase4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes: a review and meta-analysis. Diabetes Obes Metab 2012;14:762–7.
   PubMed Web of Science ®Google Scholar
• Barnett AH, et al. Key considerations around the risks and consequences of hypogly-caemia in people with type 2 diabetes. Int J Chn Pract 2010;64:1121–9.
   PubMed Web of Science ®Google Scholar
• Desouza CV, et al. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care 2010; 33:1389–94.
   PubMed Web of Science ®Google Scholar
• Zoungas S, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010;363:1410–8.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092–100.
   PubMed Web of Science ®Google Scholar
• Nauck M, et al. Efficacy and safety compari-son of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009;32:84–90.
   PubMed Web of Science ®Google Scholar
• Charbonnel B, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inad-equately controlled with metformin alone. Diabetes Care 2006;29:2638–43.
   PubMed Web of Science ®Google Scholar
• Bosi E, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007;30: 890–5.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, et al. The efficacy and safety of saxagliptin when added to metformin ther-apy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009;32:1649–55.
   PubMed Web of Science ®Google Scholar
• Taskinen MR, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a random-ized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011;13:65–74.
   PubMed Web of Science ®Google Scholar
• Ahrén B, et al. Vildaglipdn enhances islet responsiveness to both hyper- and hypo-glycemia in patients with type 2 diabetes. J Clin Endocrinol Metab 2009;94:1236–43.
   PubMed Web of Science ®Google Scholar
• Dore DD, et al. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009;25: 1019–27.
   PubMed Web of Science ®Google Scholar
• Drucker DJ, et al. The safety of incretin-based therapies - review of the scientific evidence. J Clin Endocrinol Metab 201196: 2027–31.
   Google Scholar
• Stratton IM, et al. Association of glycaemia with macrovascular and microvascular com-plications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321:405–12.
   PubMed Web of Science ®Google Scholar
• Usscher JR, Drucker DJ. Cardiovascular biol-ogy of the incretin system. Endocr Rev 2012;33:187–215.
   PubMed Web of Science ®Google Scholar
• Mannucci E, Dicembrini I. Incredn-based therapies and cardiovascular risk. Curr Med Res Opin 2012;28:715–21.
   PubMed Web of Science ®Google Scholar
• Lorber D. GLP- J receptor agonists: effects on cardiovascular risk reduction. Cardiovasc Ther 2012 Jul 30. doi: 10.1111/cdr.12000. [Epub ahead of print.]
   Google Scholar
• Monami M, et al. Dipeptidyl peptidase4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2013;15:112–20.
   PubMed Web of Science ®Google Scholar
• Ahrén B. Are sulfonylureas less desirable than DPP-4 inhibitors as add-on to met-formin in the treatment of type 2 diabetes? Curr Diabet Rep 2011;11:83–90.
   PubMed Web of Science ®Google Scholar
• Ferrannini E, et al. Fifty-two week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2009;11: 157–66.
   PubMed Web of Science ®Google Scholar
• Fonseca V, et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007;50:1148–55.
   PubMed Web of Science ®Google Scholar
• Vilsboll T, et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2010;12:167–77.
   PubMed Web of Science ®Google Scholar
• Balena R, et al. Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature. Diabetes Obes Metab 2012 Oct 15. doi: 10.1111/dom.12025. [Epub ahead of print.]
   Google Scholar
• Berlie H, et al. Glucagon-like peptide-1 receptor agonists as add-on therapy to basal insulin in patients with type 2 diabetes: a sys-tematic review. Diabetes Metab Syndr Obes 2012;5:165–74.
   PubMedGoogle Scholar
• Barnett A, et al.. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Cuff Med Res Opin 2012;28: 513–23.
   Google Scholar
• Inzucchi SE, et al. Management of hypergly-caemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55: 1577–96.
   PubMed Web of Science ®Google Scholar
• Paolisso G, et al. Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks? Adv Ther 2012;29: 218–33.
   Google Scholar
• Mathieu C, Bollaerts K. Andhyperglycaemic therapy in elderly patients with type 2 dia-betes: potential role of incretin mimetics and DPP-4 inhibitors. Int J Clin Pract 2007;154:29–37.
   Web of Science ®Google Scholar
• Sisson EM. Liraglutide: clinical pharmacol-ogy and considerations for therapy. Pharmacother 2011;31:896–911.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. DPP4 inhibitors in the manage-ment of type 2 diabetes: a critical review of head-to-head studies. Diabetes Metab 2012; 38:89–101.
   PubMed Web of Science ®Google Scholar
• Gantz I, et al. Effect of MK-3102, a novel once-weekly DPP-4 inhibitor, over 12 weeks in patients with type 2 diabetes mellitus. Diabetologia 2012;55 (Suppl 1):551.
   Google Scholar
• Issa CM, Azar ST. Possible role of GLP-1 and its agonists in the treatment of type 1 diabetes mellitus. Curr Diab Rep 2012;12: 560–7.
   PubMed Web of Science ®Google Scholar
• Farngren J, et al. Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypo-glycemia in type 1 diabetes. J Clin Endocrinol Metab 2012;97:3799–806.
   PubMed Web of Science ®Google Scholar
• Astrup A, et al. Effects of liraglutide in the treatment of obesity: a randomized, double-blind, placebo-controlled study. Lancet 2009; 374:1606–16.
   PubMed Web of Science ®Google Scholar
• Harkavyui A, Whitton PS. Glucagon-like peptide 1 receptor stimulation as a means of neuroprotecdon. Br J Pharmacol 2010;159: 495–501.
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Rosen CE Glucagon-like pep-tide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology. Diabetologia 2011;54:2471–4.
   PubMed Web of Science ®Google Scholar
• Ahrén B. The incretin-based therapy: novel avenues - novel targets. Diabetes Obes Metab 2011;13(Suppl 1):158–66.
   PubMed Web of Science ®Google Scholar
• Bergenstal RM, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010;376:431–9.
   PubMed Web of Science ®Google Scholar